Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome
Recruiting
N/A
Interventional Study
Basal Cell Carcinoma of Skin, Site Unspecified
Epidermoid Carcinoma
Lynch Syndrome
Muir-Torre Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 150 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Nīmes · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The main aim of this study is to determine the prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome (LS) confirmed by genetic analysis. Other aims include describing the dermatological clinical manifestations of these patients in order to describe any possible new cutaneous manifestations of this syndrome. Another aim is to use molecular biology (microsatellite…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patient with a germline alteration of one of the MMR (MisMatch Repair) pathway genes (MLH1, PMS2, MSH2, MSH6) proven by constitutional genetic analysis (genetically authenticated Lynch syndrome).
* Patient followed at Nîmes University Hospital.
* Patient having given free and …
Contacts